Eris Lifesciences Ltd

NSE: ERIS · BSE: 540596 · Pharmaceuticals & Biotechnology · 41 announcements

Share price: ₹1,143.10
Market cap: ₹15,859 Cr
Revenue (annual): ₹3,129 Cr
Net profit (annual): ₹619.5 Cr
P/E (TTM): 24.6×Sector 47.4×
Promoter holding: 54.14%+0.22% QoQ
FII holding: 5.76%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 7 Employee Stock Options 6 Debt & Borrowing 6 Annual General Meeting 5 Financial Results 4 Management Change 3 Other Announcement 2 Credit Rating 2 Price Movement Clarification 1 Legal & Regulatory 1 Dividend 1 Board Meeting Date 1 Annual Report 1 Adverse Business Impact 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

1 announcement with these filters

20 Apr 2026 22:13 IST BSE

Adverse Business Impact

Eris Lifesciences Adverse Business Impact

Eris Lifesciences' subsidiary, Swiss Parenterals Ltd, received non-compliance observations from HALMED, Croatia, following inspections of its Ahmedabad units. The company will execute remediation actions to reinstate approvals. While existing business impact is minimal, the observations will delay the commercialization of the EU-CDMO product pipeline.

Read the filing ↗